AstraZeneca

SOUTHAMPTON, 14-Aug-2017 — /EuropaWire/ — Patients with a common type of fast-growing cancer are being given fresh hope in a new clinical trial. Scientists at the University of Southampton are, for the first time, to trial a new experimental drug, in … Read the full press release →

RIGA, 11-Aug-2017 — /EuropaWire/ — In July, global bond market was demonstrating multidirectional movements. One of the key topics determining performance of any market was the forgotten issue of exchange rates. ECB Head Mario Draghi’s announcement at the end of … Read the full press release →

CAMBRIDGE, 07-Aug-2017 — /EuropaWire/ — AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for acalabrutinib, … Read the full press release →

SWINDON, 01-Aug-2017 — /EuropaWire/ — NERC has appointed seven new members to its Innovation Advisory Board to replace those who have completed their term. The Innovation Advisory Board advises NERC on its strategy for strengthening the delivery of economic growth and … Read the full press release →

COVENTRY, 20-Apr-2017 — /EuropaWire/ — A space plane designer, someone who manipulated individual atoms to form what became an iconic image, and a leading policy maker on global climate change are among those to receive honorary degrees from the University of … Read the full press release →

LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release →

Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level LONDON, 03-Mar-2017 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg … Read the full press release →

STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders. A large scale analysis of … Read the full press release →

LONDON, 28-Jun-2016 — /EuropaWire/ — AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine (FluMist … Read the full press release →

LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of a new antibiotic, CAZ AVI 2g/0.5g powder. CAZ … Read the full press release →

SUBJECT: REGULATORY LANDSCAPE FOR PHARMA MANUFACTURERS AMSTERDAM, 30-Mar-2016 — /EuropaWire/ — Christoph Krähenbühl, senior director, 3C Excellis, will be a featured speaker at Systech International’s upcoming global conference in Amsterdam titled UNIQUITY Europe, 2016, focused on serialization, global brand protection … Read the full press release →

Missed primary efficacy endpoint; fewer events observed in the Brilinta arm but trend did not reach statistical significance Consistent safety profile LONDON, 25-Mar-2016 — /EuropaWire/ — AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique(ticagrelor) 90mg … Read the full press release →

LONDON, 26-Jan-2016 — /EuropaWire/ — Three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation) and the technology transfer offices of three world-leading universities (Imperial College London, University of Cambridge and UCL) have joined forces with a combined £40 million to … Read the full press release →

LONDON, 10-12-2015 — /EuropaWire/ — AstraZeneca today announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis has developed the service in close clinical … Read the full press release →

LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus … Read the full press release →

Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP. Sandoz’s budesonide inhalation suspension product is indicated … Read the full press release →

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France,  30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release →

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015. Overall, data indicated … Read the full press release →

LONDON, 4-5-2015 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. … Read the full press release →

Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients in 15 countries LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the … Read the full press release →